Inflammatory mechanisms associated with prostatic inflammation and lower urinary tract symptoms

Current Prostate Reports

Volumn 6, Issue 2, 2008, Pages 67-73

  St Sauver, Jennifer L ^a   Jacobsen, Steven J ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; CYCLOOXYGENASE 2; DOXAZOSIN; FINASTERIDE; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; INTERLEUKIN 17; LOXOPROFEN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN BCL 2; ROFECOXIB; SABAL EXTRACT;

AGING; ANTIINFLAMMATORY ACTIVITY; BLADDER DYSFUNCTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; GENE EXPRESSION; HUMAN; INFLAMMATION; LOWER URINARY TRACT SYMPTOM; MONOTHERAPY; NONHUMAN; PHYTOTHERAPY; PROSTATE BIOPSY; PROSTATE HYPERTROPHY; PROSTATE SURGERY; PROTEIN EXPRESSION; REVIEW; SABAL; URINE RETENTION;

EID: 58149295325     PISSN: 15441865     EISSN: 1544225X     Source Type: Journal    
DOI: 10.1007/s11918-008-0011-5     Document Type: Review

References (59)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 1984, 132:474-479.
2. Sarma AV, Wei JT, Jacobson DJ, et al.: Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men's Health Study. Urology 2003, 61:1086-1091.
3. Wei JT, Calhoun E, Jacobsen SJ: Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005, 173:1256-1261.
4. Jacobsen SJ, Girman CJ, Guess HA, et al.: New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States. Arch Intern Med 1995, 155:477-481.
5. Kohnen PW, Drach GW: Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol 1979, 121:755-760.
6. Di Silverio F, Gentile V, De Matteis A, et al.: Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 2003, 43:164-175.
7. Gerstenbluth RE, Seftel AD, MacLennan GT, et al.: Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol 2002, 167:2267-2270.
8. Anim JT, Kehinde EO, Prasad A, et al.: Relationship between serum prostate specific antigen and the pattern of inflammation in both benign and malignant prostatic disease in Middle Eastern men. Int Urol Nephrol 2006, 38:27-32.
9. •• Roehrborn C, Kaplan SA, Noble WD, et al.: The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results of the MTOP study [abstract]. J Urol 2005, 173:204. This provocative abstract provides important data describing a temporal relationship between the presence of prostatic inflammation and the development of adverse urologic outcomes.
10. •• Rohrmann S, De Marzo AM, Smit E, et al.: Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 2005, 62:27-33. This is the only currently available study to examine the association between a nonprostatic measure of inflammation and LUTS.
11. • Nickel JC, Roehrborn CG, O'Leary MP, et al.: Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. J Urol 2007, 178:896-900; discussion 900-891. This study found small, nonclinically significant associations between the presence of prostatic inflammation and symptoms of prostatitis, including presence of urinary symptoms.
12. Collins GN, Lee RJ, McKelvie GB, et al.: Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Br J Urol 1993, 71:445-450.
13. St Sauver JL, Jacobson DJ, Girman CJ, et al.: Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort. J Urol 2006, 175:1018-1022; discussion 1022.
14. • Tuncel A, Uzun B, Eruyar T, et al.: Do prostatic infarction, prostatic inflammation and prostate morphology play a role in acute urinary retention? Eur Urol 2005, 48:277-283; discussion 283-274. This case-controlled study found an association between presence of prostatic inflammation and AUR independent of prostate volume.
15. • Kefi A, Koseoglu H, Celebi I, et al.: Relation between acute urinary retention, chronic prostatic inflammation and accompanying elevated prostate-specific antigen. Scand J Urol Nephrol 2006, 40:155-160. Together with Tuncel et al [14•], this case-controlled study also found an association, independent of prostate volume, between presence of prostatic inflammation and AUR.
16. • Mishra VC, Allen DJ, Nicolaou C, et al.: Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 2007, 100:327-331. These data add to the results of Tuncel et al. [14•] and Kefi et al. [15•] in establishing a role for prostatic inflammation in AUR.
17. Kessler OJ, Keisari Y, Servadio C, Abramovici A: Role of chronic inflammation in the promotion of prostatic hyperplasia in rats. J Urol 1998, 159:1049-1053.
18. Steiner G, Gessl A, Kramer G, et al.: Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Urol 1994, 151:480-484.
19. Bostwick DG, de la Roza G, Dundore P, et al.: Intraepithelial and stromal lymphocytes in the normal human prostate. Prostate 2003, 55:187-193.
20. Anim JT, Udo C, John B: Characterisation of inflammatory cells in benign prostatic hyperplasia. Acta Histochem 1998, 100:439-449.
21. •• Kramer G, Mitteregger D, Marberger M: Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007, 51:1202-1216. This interesting review article proposes that BPH meets several characteristic criteria for immune inflammatory diseases.
22. Handisurya A, Steiner GE, Stix U, et al.: Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate 2001, 49:251-262.
23. Kakehi Y, Segawa T, Wu XX, et al.: Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia. Prostate 2004, 59:351-356.
24. Taoka R, Tsukuda F, Ishikawa M, et al.: Association of prostatic inflammation with down-regulation of macrophage inhibitory cytokine-1 gene in symptomatic benign prostatic hyperplasia. J Urol 2004, 171:2330-2335.
25. Steiner GE, Newman ME, Paikl D, et al.: Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003, 56:171-182.
26. • Penna G, Mondaini N, Amuchastegui S, et al.: Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/ chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 2007, 51:524-533; discussion 533. This manuscript attempts to bridge basic science and clinical data, by both noting an increased level of IL-8 in BPH patients and an association between IL-8 level and urinary symptoms.
27. Royuela M, Ricote M, Parsons MS, et al.: Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate. J Pathol 2004, 202:41-49.
28. Kramer G, Steiner GE, Handisurya A, et al.: Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002, 52:43-58.
29. Steiner GE, Stix U, Handisurya A, et al.: Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest 2003, 83, 1131-1146.
30. Giri D, Ittmann M: Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am J Pathol 2001, 159:139-147.
31. Castro P, Xia C, Gomez L, et al.: Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate 2004, 60:153-159.
32. Faour WH, Mancini A, He QW, Di Battista JA: T-cell-derived interleukin-17 regulates the level and stability of cyclooxygenase-2 (COX-2) mRNA through restricted activation of the p38 mitogen-activated protein kinase cascade: role of distal sequences in the 3′-untranslated region of COX-2 mRNA. J Biol Chem 2003, 278:26897-26907.
33. Wang W, Bergh A, Damber JE: Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 2004, 61:60-72.
34. •• Lin VK, Wang SY, Roehrborn C: Alpha adrenergic stimulation regulates cox-2 expression in prostate stroma cells (abstract). J Urol 2005, 173 (Suppl):390. This interesting abstract has not been published in manuscript form, but suggests a fascinating association between upregulation of the α-adrenergic pathway and COX-2.
35. Kyprianou N, Tu H, Jacobs SC: Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol 1996, 27:668-675.
36. • Shariat SF, Ashfaq R, Roehrborn CG, et al.: Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. J Urol 2005, 174:2046-2050. This paper begins to explore the role of apoptotic biomarkers in BPH beyond BCL-2.
37. Rittmaster RS, Norman RW, Thomas LN, Rowden G: Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab 1996, 81:814-819.
38. Huynh H: Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins. Int J Oncol 2002, 20:1297-1303.
39. Tahmatzopoulos A, Kyprianou N: Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality? Prostate 2004, 59:91-100.
40. Garrison JB, Kyprianou N: Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res 2006, 66:464-472.
41. • Roehrborn CG: Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis 2006, 9:121-125. This study did not find a clinical association between the potential apoptotic effects of alfuzosin and decreased prostate volume; however, 3 months' treatment may not have been long enough to observe any clinical changes in prostate volume.
42. •• St. Sauver JL, Jacobson D, McGree ME, et al.: Protective association between non-steroidal anti-inflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol 2006, 164:760-768. This paper examines the association between NSAID use and urologic outcomes, finding a protective association between daily use of NSAID and prostate volume, LUTS, and AUR, suggesting that NSAIDs may be useful in preventing some of these conditions.
43. • Minnery CH, Getzenberg RH: Benign prostatic hyperplasia cell line viability and modulation of jm-27 by doxazosin and Ibuprofen. J Urol 2005, 174:375-379. These authors provide basic science data to suggest that both doxazosin and ibuprofen act through JM-27 to reduce prostate growth via increased cell death and increased apoptosis.
44. Vela Navarrete R, Garcia Cardoso JV, Barat A, et al.: BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol 2003, 44:549-555.
45. Maggi CA, Evangelista S, Grimaldi G, et al.: Evidence for the involvement of arachidonic acid metabolites in spontaneous and drug-induced contractions of rat urinary bladder. J Pharmacol Exp Ther 1984, 230:500-513.
46. Palea S, Toson G, Pietra C, et al.: Pharmacological characterization of thromboxane and prostanoid receptors in human isolated urinary bladder. Br J Pharmacol 1998, 124:865-872.
47. Park JM, Yang T, Arend LJ, et al.: Obstruction stimulates COX-2 expression in bladder smooth muscle cells via increased mechanical stretch. Am J Physiol 1999, 276: F129-136.
48. Bouchelouche K, Alvarez S, Andersen L, et al.: Monocyte chemoattractant protein-1 production by human detrusor smooth muscle cells. J Urol 2004, 171:462-466.
49. • Bouchelouche K, Alvarez S, Horn T, et al.: Human detrusor smooth muscle cells release interleukin-6, interleukin-8, and RANTES in response to proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha. Urology 2006, 67:214-219. This study provides basic science data indicating that detrusor smooth muscle cells are able to release proinflammatory cytokines.
50. Takagi-Matsumoto H, Ng B, Tsukimi Y, Tajimi M: Effects of NSAIDs on bladder function in normal and cystitis rats: a comparison study of aspirin, indomethacin, and ketoprofen. J Pharmacol Sci 2004, 95:458-465.
51. • Angelico P, Guarneri L, Velasco C, et al.: Effect of cyclooxygenase inhibitors on the micturition reflex in rats: correlation with inhibition of cyclooxygenase isozymes. BJU Int 2006, 97:837-846. This study provides animal model data to suggest that efficacy of COX inhibitors in treating rat micturition conditions is related primarily to action on the COX-2 enzyme.
52. Erdogru T, Celik-Ozenci C, Seval Y, et al.: The restorative effect of a selective cyclooxygenase-2 inhibitor on urothelial cell-cell interactions after partial bladder outlet obstruction in rats. BJU Int 2005, 95:664-669.
53. Meini S, Lecci A, Cucchi P, et al.: Inflammation modifies the role of cyclooxygenases in the contractile responses of the rat detrusor smooth muscle to kinin agonists. J Pharmacol Exp Ther 1998, 287:137-143.
54. Cardozo LD, Stanton SL: A comparison between bromocriptine and indomethacin in the treatment of detrusor instability. J Urol 1980, 123:399-401.
55. Cardozo LD, Stanton SL, Robinson H, Hole D: Evaluation of flurbiprofen in detrusor instability. Br Med J 1980, 280:281-282.
56. Araki T, Yokoyama T, Kumon H: Effectiveness of a nonsteroidal anti-inflammatory drug for nocturia on patients with benign prostatic hyperplasia: a prospective non-randomized study of loxoprofen sodium 60 mg once daily before sleeping. Acta Med Okayama 2004, 58:45-49.
57. •• Di Silverio F, Bosman C, Salvatori M, et al.: Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol 2005, 47:72-78; discussion 78-79. This small clinical trial provides interesting data to suggest that NSAIDs may be a useful adjunct therapy for treating BPH-related LUTS.
58. •• Verhamme KM, Dieleman JP, Van Wijk MA, et al.: Nonsteroidal anti-inflammatory drugs and increased risk of acute urinary retention. Arch Intern Med 2005, 165:1547-1551. This large, retrospective, case-controlled study provides cautionary data suggesting that, in at least some men, new use of NSAIDs may actually trigger AUR.
59. Partin JV, Anglin IE, Kyprianou N: Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction. Br J Cancer 2003, 88:1615-1621.